CymaBay Therapeutics, Inc.

CBAY · NASDAQ
Analyze with AI
12/31/2023
9/30/2023
6/30/2023
3/31/2023
Operating Activities
Net Income-$42-$34-$1-$29
Dep. & Amort.$0$0$0$0
Deferred Tax-$4-$2-$2$0
Stock-Based Comp.$5$4$3$3
Change in WC$7$1-$31$28
Other Non-Cash$7$5$5$3
Operating Cash Flow-$27-$26-$25$6
Investing Activities
PP&E Inv.-$0$0-$0-$0
Net Acquisitions$0$0-$1-$1
Inv. Purchases-$116-$30-$39-$121
Inv. Sales/Matur.$74$45$40$61
Other Inv. Act.$0$15$1$1
Investing Cash Flow-$42$15$1-$61
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$3$243$1$92
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$3$249$1$93
Financing Cash Flow$3$249$1$93
Forex Effect-$0$0$27$0
Net Chg. in Cash-$67$238-$24$39
Supplemental Information
Beg. Cash$274$35$59$20
End Cash$207$274$35$59
Free Cash Flow-$28-$26-$26$6
CymaBay Therapeutics, Inc. (CBAY) Financial Statements & Key Stats | AlphaPilot